Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and ... s aura6000 to improvements on measures of OSA severity and blood oxygen after six months of ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

Lincare, the nation’s largest distributor of home oxygen equipment, has repeatedly violated Medicare rules and probation ...

A recent study showed that mouth taping, as mimicked by closing the mouth in people with sleep apnea, may not be the cure-all ...

Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA ... significant improvement in the apnea-hypopnea index ...

An unhealthy diet and an indolent life are well known causes of heart disease and stroke. But sleep apnea—where people ...

I’m sorry to hear your CPAP mask is keeping you awake at night, but I’m happy to hear that you’re addressing your obstructive ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea. In the OSPREY study, apnea-hypopnea index and oxygen ...